496 related articles for article (PubMed ID: 30181337)
1. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
Trujillo JA; Sweis RF; Bao R; Luke JJ
Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
[TBL] [Abstract][Full Text] [Related]
2. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
3. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
Gajewski TF
Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
[TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
[TBL] [Abstract][Full Text] [Related]
5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
Casey DL; Cheung NV
Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Spranger S
Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
[TBL] [Abstract][Full Text] [Related]
8. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
9. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
10. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
Li X; Xiang Y; Li F; Yin C; Li B; Ke X
Front Immunol; 2019; 10():2293. PubMed ID: 31616443
[TBL] [Abstract][Full Text] [Related]
11. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
Kumar A; Chamoto K; Chowdhury PS; Honjo T
Elife; 2020 Mar; 9():. PubMed ID: 32122466
[TBL] [Abstract][Full Text] [Related]
12. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
Olson DJ; Luke JJ
Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
[No Abstract] [Full Text] [Related]
13. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
14. Obstacles to T cell migration in the tumor microenvironment.
Nicolas-Boluda A; Donnadieu E
Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
[TBL] [Abstract][Full Text] [Related]
15. Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy in cancer. Current prospects, challenges and new horizons].
Dalotto-Moreno T; Blidner AG; Girotti MR; Maller SM; Rabinovich GA
Medicina (B Aires); 2018; 78(5):336-348. PubMed ID: 30285926
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
Take Y; Koizumi S; Nagahisa A
Front Immunol; 2020; 11():324. PubMed ID: 32210957
[TBL] [Abstract][Full Text] [Related]
18. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
[TBL] [Abstract][Full Text] [Related]
19. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunoediting and resistance to T cell-based immunotherapy.
O'Donnell JS; Teng MWL; Smyth MJ
Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]